Showing 1 - 20 of 23 Items
Showing 1 - 20 of 23 Items
Sort By: Relevance
Journal Article
|Case Report/Series
2024-01-09 • Clinical Infectious Diseases
2024-01-09 • Clinical Infectious Diseases
BACKGROUND
HIV patients with recurrent visceral leishmaniasis (VL) could potentially drive Leishmania transmission in areas with anthroponotic transmission such as East-Africa, but s...
HIV patients with recurrent visceral leishmaniasis (VL) could potentially drive Leishmania transmission in areas with anthroponotic transmission such as East-Africa, but s...
Journal Article
|Review
2024-01-01 • Lancet Infectious Diseases
2024-01-01 • Lancet Infectious Diseases
For the past 15 years, trials of combination therapy options for visceral leishmaniasis have been conducted with the aim of identifying effective, and safe treatment regimens that were s...
Journal Article
|Commentary
2023-03-23 • PLOS Neglected Tropical Diseases
2023-03-23 • PLOS Neglected Tropical Diseases
Journal Article
|Research
2017-06-05 • PLOS One
2017-06-05 • PLOS One
BACKGROUND
In Ethiopia, case fatality rates among subgroups of visceral leishmaniasis (VL) patients are high. A clinical prognostic score for death in VL patients could contribute to...
In Ethiopia, case fatality rates among subgroups of visceral leishmaniasis (VL) patients are high. A clinical prognostic score for death in VL patients could contribute to...
Journal Article
|Research
2014-06-26 • PLOS Neglected Tropical Diseases
2014-06-26 • PLOS Neglected Tropical Diseases
Visceral Leishmaniasis (VL) is an important protozoan opportunistic disease in HIV patients in endemic areas. East Africa is second to the Indian subcontinent in the global VL caseload a...
Journal Article
|Research
2018-05-25 • PLOS Neglected Tropical Diseases
2018-05-25 • PLOS Neglected Tropical Diseases
North-west Ethiopia faces the highest burden world-wide of visceral leishmaniasis (VL) and HIV co-infection. VL-HIV co-infected patients have higher (initial) parasitological failure and...
Protocol
|Research Protocol
2018-07-01
2018-07-01
2.1 OBJECTIVES
2.1.1 General objective:
To document the effectiveness, safety and feasibility of monthly PM secondary prophylaxis (PSP) in VL/HIV co-infected patients t...
2.1.1 General objective:
To document the effectiveness, safety and feasibility of monthly PM secondary prophylaxis (PSP) in VL/HIV co-infected patients t...
Protocol
|Research Protocol
2018-07-01
2018-07-01
Aim To study the asymptomatic period preceding the onset of active VL in HIV‐infected individuals from VL endemic regions in Ethiopia as an avenue to develop an evidence‐based screen and...
Journal Article
|Commentary
2014-07-17 • PLOS Neglected Tropical Diseases
2014-07-17 • PLOS Neglected Tropical Diseases
Journal Article
|Research
2017-03-18 • Transactions of the Royal Society of Tropical Medicine and Hygiene
2017-03-18 • Transactions of the Royal Society of Tropical Medicine and Hygiene
BACKGROUND
The 2014/2015 Ebola outbreak was the most sustained in history. In Guinea, we compared trends in family planning, antenatal care, and institutional deliveries over the per...
The 2014/2015 Ebola outbreak was the most sustained in history. In Guinea, we compared trends in family planning, antenatal care, and institutional deliveries over the per...
Journal Article
|Commentary
2019-02-08 • BMJ Global Health
2019-02-08 • BMJ Global Health
SUMMARY BOX
The international community has pledged through the Sustainable Development Goals to eliminate neglected tropical diseases by 2030.
Authors from 19 institut...
The international community has pledged through the Sustainable Development Goals to eliminate neglected tropical diseases by 2030.
Authors from 19 institut...
Protocol
|Research Protocol
2018-07-01
2018-07-01
General Objectives
The overall objective of this trial is to identify a safe and effective treatment for VL in HIV coinfected
patients.
Primary Objective:
To evaluate...
The overall objective of this trial is to identify a safe and effective treatment for VL in HIV coinfected
patients.
Primary Objective:
To evaluate...
Journal Article
|Research
2019-01-17 • PLOS Neglected Tropical Diseases
2019-01-17 • PLOS Neglected Tropical Diseases
BACKGROUND
Visceral leishmaniasis (VL) in human immunodeficiency virus (HIV) co-infected patients requires special case management. AmBisome monotherapy at 40 mg/kg is recommended by...
Visceral leishmaniasis (VL) in human immunodeficiency virus (HIV) co-infected patients requires special case management. AmBisome monotherapy at 40 mg/kg is recommended by...
Journal Article
|Research
2019-02-21 • PLOS Neglected Tropical Diseases
2019-02-21 • PLOS Neglected Tropical Diseases
BACKGROUND:
The long-term treatment outcome of visceral leishmaniasis (VL) patients with HIV co-infection is complicated by a high rate of relapse, especially when the CD4 count is ...
The long-term treatment outcome of visceral leishmaniasis (VL) patients with HIV co-infection is complicated by a high rate of relapse, especially when the CD4 count is ...
Journal Article
|Research
2017-06-21 • Public Health Action
2017-06-21 • Public Health Action
Setting: All health centres in Macenta District, rural Guinea. Objective: To compare stock-outs of vaccines, vaccine stock cards and the administration of various childhood vaccines acro...
Journal Article
|Research
2018-03-29 • Frontiers in Cellular and Infection Microbiology
2018-03-29 • Frontiers in Cellular and Infection Microbiology
BACKGROUND
Biomarkers predicting the risk of VL treatment failure and relapse in VL/HIV coinfected patients are needed. Nested within a two-site clinical trial in Ethiopia (2011-2015...
Biomarkers predicting the risk of VL treatment failure and relapse in VL/HIV coinfected patients are needed. Nested within a two-site clinical trial in Ethiopia (2011-2015...
Journal Article
|Research
2017-06-13 • Transactions of the Royal Society of Tropical Medicine and Hygiene
2017-06-13 • Transactions of the Royal Society of Tropical Medicine and Hygiene
BACKGROUND
Visceral leishmaniasis (VL) patients with HIV co-infection should receive antiretroviral treatment (ART). However, the best timing for initiation of ART is not known. Amon...
Visceral leishmaniasis (VL) patients with HIV co-infection should receive antiretroviral treatment (ART). However, the best timing for initiation of ART is not known. Amon...
Journal Article
|Research
2017-10-30 • Clinical Infectious Diseases
2017-10-30 • Clinical Infectious Diseases
BACKGROUND
East Africa, where Leishmania donovani is prevalent, faces the highest burden world-wide of visceral leishmaniasis (VL) and human immunodeficiency virus (HIV) coinfection...
East Africa, where Leishmania donovani is prevalent, faces the highest burden world-wide of visceral leishmaniasis (VL) and human immunodeficiency virus (HIV) coinfection...
Journal Article
|Research
2017-09-13 • Clinical Infectious Diseases
2017-09-13 • Clinical Infectious Diseases
We have conducted a single-arm trial evaluating monthly pentamidine secondary prophylaxis (PSP) to prevent visceral leishmaniasis (VL) relapse in Ethiopian HIV-patients. Outcomes at 12 m...
Journal Article
|Research
2018-03-16 • Open Forum Infectious Diseases
2018-03-16 • Open Forum Infectious Diseases
Visceral leishmaniasis (VL)-human immunodeficiency virus (HIV) coinfection remains a major problem in Ethiopia, India, and Brazil. Tuberculosis (TB), a treatable factor, could contribute...